

## Professional services, fees and claims data for government-sponsored pharmacy programs, by province • As of January 20, 2023

	British Columbia	Alberta	Saskatchewan
<b>Care plans</b>		\$100 per Comprehensive Annual Care Plan (CACP) (295,830 claims); \$60 per Standard Medication Management Assessment (SMMA) (39,862); \$20 per follow-up, max. 12 annually (1,274,813 for CACPs; 130,929 for SMMA); \$60 per SMMA for Diabetes and \$20 per follow-up, max. 12 annually (19,465 combined)	
<b>Medication reviews/management</b>	\$60 per Medication Review - Standard, max. 2 annually, 6 mths apart (176,721 claims); \$70 per Medication Review - Pharmacist Consultation, max. 2 annually, 6 mths apart (14,161); \$15 per Medication Review Follow-Up, max. 4 annually (10,879)	Medication reviews a component of CACPs and SMMA (see Care plans above)	<b>\$60 per Medication Assessment (seniors) (6,961 claims), max. 1 annually; \$20 per follow-up, max. 2 annually (1,707); \$60 per Medication Assessment and Compliance Packaging (1,209)</b>
<b>Pharmaceutical opinions</b>			
<b>Vaccination</b>	\$12.10 (1,026,623 claims for flu, 17,458 for pneumonia, 35,773 for other); \$18 for COVID-19 inc. \$5.90 to offset costs (1,242,610)	\$15 inc. \$2 to offset costs until Mar. 31, 2022 (898,325 claims for flu, 13,120 for pneumonia, 11,753 for Tdap); \$25 or \$35 (weekends/stat holidays) for COVID-19 (4,338,135); authority for other vaccinations, inc. travel vaccines	\$14 for flu (176,973 claims) \$20 for COVID-19 (627,882); authority for other vaccinations, inc. travel vaccines
<b>Administration of drugs by injection</b>	Authority to administer drugs by injection	\$20 per administration (271,560 claims)	\$13 for medroxyprogesterone (5,856 claims)
<b>Prescribing: renewals and adaptations</b>	\$10 to renew (276,066 claims) or adapt (36,216), max. 2/drug every 6 months or one-time renewal for controlled substances	\$20 to renew or adapt (inc. altering insulin orders and discontinuations) (1,169,116 claims for renewals; 143,757 for adaptations)	\$6 to renew, alter dosage form, max. 4/28 days, or alter missing information, max. 1/28 days; \$10 to continue prescription in emergency, max. 1/28 days (399,830 claims for all Rx authority inc. reconciliations with prescribing [see "Prescribing authority: initial access"])
<b>Prescribing: common or minor ailments</b>	Authority pending to assess and prescribe for minor ailments and contraceptives; implementation anticipated in spring 2023	As part of CACPs and SMMA by those with additional prescribing authority (APA); outside of CACPs and SMMA, \$25 per assessment resulting in a prescription by those with APA (claims inc. under prescribing for initial access)	\$18 per assessment resulting in a prescription, for 27 conditions (32,304 claims)
<b>Prescribing: initial access or to manage ongoing therapy</b>		\$25 per assessment for initiating prescription by those with APA (319,932 claims); \$20 per emergency prescription (23,834); \$20 per continuity of care prescription during declared "state of emergency" (0)	\$25 for medication reconciliations with prescribing (claims inc. under all Rx authority, see "Prescribing: adaptation"); authority to assess and prescribe in emergencies; authority to assess and prescribe for preventable diseases (e.g. HPV, varicella)
<b>COVID-19 prevention and treatment</b>	Selected pharmacies dispense govt-funded Paxlovid: \$30 for clinical assessment plus usual dispensing fee plus \$25 for follow-up	<ul style="list-style-type: none"> <li>All pharmacies can dispense govt-funded Paxlovid; usual dispensing fee plus \$10 to offset distribution costs</li> <li>Pharmacists with APA can prescribe Paxlovid</li> </ul>	\$18 to assess and prescribe Paxlovid or make referral plus usual dispensing fee plus \$20 to offset distribution costs (claims n/a)
<b>Therapeutic substitution</b>	\$17.20 (10,949)	\$20 per substitution (claims included under adaptations)	\$18 per substitution pending regulations
<b>Trial prescriptions &amp; refusals to fill</b>	\$10 per trial (claims n/a); \$20 per refusal (claims n/a)	\$12.15 per trial plus \$20 for follow-up (claims n/a); \$20 per refusal (2,878)	<b>\$11.85 per trial plus \$7.50 for follow-up (1 claim); 1.5X dispensing fee max. \$17.40 per refusal (27)</b>
<b>Deprescribing</b>		\$20 per discontinuation (claims inc. under adaptations)	
<b>Ordering laboratory tests</b>		Authority to order lab tests	Authority to order lab tests pending health system regulations
<b>Point of care testing (POCT)</b>			
<b>Smoking cessation</b>		\$60 for SMMA for Tobacco Cessation; \$20 per follow-up, max. 4 follow-ups annually (30,953 claims combined)	<ul style="list-style-type: none"> <li><b>Up to \$300 annually (\$1 [individual] or \$2 [group] per minute) for Partnership to Assist with the Cessation of Tobacco (PACT) (3,500 claims)</b></li> <li><b>Authority to prescribe for smoking cessation as part of minor ailments</b></li> </ul>
<b>Opioid harm reduction</b>	<ul style="list-style-type: none"> <li>\$7.70 per witnessed dose of methadone (claims n/a)</li> <li>Provincially funded naloxone available through pharmacies</li> </ul>	\$12.15 for dispensing of provincially funded naloxone (49,985 claims)	<ul style="list-style-type: none"> <li><b>\$3.50/day per witnessed dose for Methadone Managed Care (55,352 claims) and Suboxone Managed Care (15,786), max. 7 weekly</b></li> <li><b>\$16 for education for provincially funded naloxone available at selected pharmacies (720)</b></li> </ul>
<b>Other services</b>	\$15 for biosimilar counselling during 6-month transition period	\$20 per Assessment to Screen and/or Test for Infectious Disease, max. 5/day/pharmacy (note: not a POCT; currently for COVID-19 only; 1,182,340 claims)	<ul style="list-style-type: none"> <li><b>1.5X dispensing fee, max. \$17.40 for seamless care (367 claims)</b></li> <li><b>\$3.50/day for Direct Observed Therapy for Hepatitis C drugs (68)</b></li> </ul>

All content in **RED** indicates public funding is available only to eligible beneficiaries of the provincial drug plan.  
 NOTES: Information current as of January 20, 2023. Claims data are for fiscal year ending March 31, 2022 unless other stated. In **New Brunswick and Nova Scotia**, claims data for COVID-19 vaccinations are estimates since data for fiscal year ending March 31, 2022 not available at time of compilation. In **Nova Scotia**, claims data for flu vaccinations not available at time of compilation. In **Manitoba**, claims for vaccinations may include non-publicly funded vaccines. In **Québec**, private insurance plans pay the same professional service fees as the public plan, for most but not all of the services listed here. In **all provinces**, pharmacists have authority to prescribe emergency refills.

SOURCES: Provincial pharmacy associations, provincial ministries of health, Neighbourhood Pharmacy Association of Canada (Pharmacy Services and Remuneration Summary, August 2022), Canadian Pharmacists Association (Injection Authority and Vaccine Administration chart, June 2022), Neighbourhood Pharmacies COVID-19 Vaccine Update (Apr 14-20, 2022).

Made possible with financial support from



Professional services, fees and claims data for government-sponsored pharmacy programs, by province • As of January 20, 2023

	Manitoba	Ontario	Québec	New Brunswick
<b>Care plans</b>				
<b>Medication reviews/management</b>		\$60 per MedsCheck (501,152 claims); \$75 for MedsCheck for Diabetes (127,294); \$150 for MedsCheck at Home (4,942); \$25 per follow-up (86,829 for MedsCheck; 32,045 for MedsCheck for Diabetes)		\$52.50 per PharmaCheck (low-income), max. 1 annually (12,056 claims)
<b>Pharmaceutical opinions</b>		<ul style="list-style-type: none"> <li>\$15 per Pharmaceutical Opinion (114,492 claims for "Change to prescription;" 49,404 for "No change to prescription;" 11,350 for "Not filled")</li> <li>\$15 per PO during Paxlovid dispensing</li> </ul>	\$21.25 per Pharmaceutical Opinion (238,443 claims)	
<b>Vaccination</b>	\$7 (172,541 claims for flu; 3,373 for pneumonia; 960 for HPV; 3,484 for Tdap; 126 for Td); \$20 for COVID-19 (445,832) SEE NOTES	\$8.50 for flu (1,689,167 claims); \$13 for COVID-19 (7,200,000 claims) SEE NOTES; authority for other vaccinations, inc. travel vaccines	\$15.66 as of May 15, 2022, up from \$12.10, plus \$0.50 for materials (579,687 claims for flu; 1,775,148 for COVID-19; 65,351 for other)	\$13 for flu (est. 95,000 claims SEE NOTES); \$17 for COVID-19 inc. \$4 to offset costs (est. 800,000 SEE NOTES); authority for other vaccinations, inc. travel vaccines
<b>Administration of drugs by injection</b>	Authority to administer drugs by injection	Authority to administer certain drugs for education and demonstration	\$20.31 as of Apr 1, 2022, up from \$19.34 to demonstrate appropriate use (8,700 claims) or in emergencies (477)	Authority to administer drugs by injection
<b>Prescribing: renewals and adaptations</b>	Authority for continuity of care prescribing and prescription adaptations	Authority to renew and adapt	\$14.09 as of Apr 1, 2022, up from \$13.42 per renewal (30+ days), max. 2 annually (1,746,815 claims); \$22.31 as of Apr 1, 2022, up from \$21.25 per adaptation (179,365)	\$20 per renewal for 4 or more prescriptions or \$15 for 3 or \$10 for 1 or 2, max. 4 annually (claims n/a); authority to adapt
<b>Prescribing: common or minor ailments</b>	\$20 per assessment for UTIs with or without prescribing (claims n/a); authority for 13 conditions in total	\$19 (in-person) or \$15 (virtual) to assess and prescribe for 13 conditions, effective Jan. 1, 2023	\$18.04 as of Apr 1, 2022, up from \$17.18 (\$22.31 up from \$21.25 for herpes zoster, influenza and COVID-19) per assessment with or without prescribing (467,133 claims)	\$20 per assessment with or without prescribing for UTIs, max. 2 annually, and herpes zoster, max. 1 annually (claims n/a); authority for 32 conditions in total
<b>Prescribing: initial access or to manage ongoing therapy</b>	Authority for prescribing by Extended Practice pharmacists within the scope of their specialty; authority to prescribe in "state of emergency"	Authority to initiate Schedule 1 smoking cessation therapy; see Smoking cessation below for funding details for services	<ul style="list-style-type: none"> <li>To reach therapeutic target: \$17.47-\$21.99 as of Apr 1, 2022, up from \$15.64-\$20.94 for initial evaluation, max. \$45.08 annually plus \$22.56 per additional therapy (278,848 claims)</li> <li>\$19.34 for emergency contraception prescribing; \$19.34 to prescribe and administer salbutamol and nonprescription drugs in an emergency (127,911)</li> </ul>	<ul style="list-style-type: none"> <li>Authority to assess and prescribe in emergencies; for preventable diseases (e.g., HPV, varicella)</li> <li>\$20 per annual assessment with or without prescribing for Contraception Management; \$20 per follow-up with change in prescription, max. 1 annually; \$12 per follow-up with no change, discontinuation and/or referral, max. 1 annually</li> </ul>
<b>COVID-19 prevention and treatment</b>	Participating pharmacies dispense govt-funded Paxlovid; \$15 or usual dispensing fee (if lower)	<ul style="list-style-type: none"> <li>\$19 per assessment with or without prescribing Paxlovid as of Dec. 12, 2022</li> <li>\$13.25 to dispense govt-funded Paxlovid</li> <li>\$13.25 to supply govt-funded Evusheld for prevention</li> </ul>	<ul style="list-style-type: none"> <li>\$22.31 as of Apr 1, 2022, up from \$21.25 per assessment with or without prescribing as part of minor ailments</li> <li>\$200 one-time set-up fee to dispense Paxlovid; usual dispensing fee plus \$10 for first 30,000 Rx (\$5 after 30,000)</li> </ul>	\$20 per assessment with or without prescribing Paxlovid, or to adapt, complete or correct prescription, max. 3 annually
<b>Therapeutic substitution</b>			\$18.04 as of Apr 1, 2022, up from \$17.18 (84,679 claims)	Authority to substitute
<b>Trial prescriptions &amp; refusals to fill</b>		\$15 per refusal as part of Pharmaceutical Opinions (see above)	\$9.38 or \$10.03 per trial plus \$8.98 or \$9.62 for follow-up (claims n/a); \$9.62 per refusal (37,031 claims)	
<b>Deprescribing</b>				
<b>Ordering laboratory tests</b>	Authority to order lab tests		Authority to order lab tests	Authority to order and administer lab tests
<b>Point of care testing (POCT)</b>		<ul style="list-style-type: none"> <li>Authority to perform certain POCTs (glucose, HbA1C, lipids, and PT/INR) for medication management</li> <li>For COVID-19: \$42 for in-store PCR test; \$20 for screening if patient determined to be ineligible for PCRT (477,221 claims)</li> </ul>	Authority to obtain throat specimen for medication management	Authority to witness self-administration of rapid antigen test for COVID-19 and certify result
<b>Smoking cessation</b>	\$100 to assess and prescribe for smoking cessation; \$20 per follow-up, max. 9 annually	Up to \$125 annually: \$40 for initial consult (737 claims); \$15 per primary follow-up, max. 3 (1,024); \$10 per secondary follow-up, max. 4 (541)	\$18.04 as of Apr 1, 2022, up from \$17.18 to prescribe for smoking cessation (claims inc. under minor ailments)	Authority to prescribe for smoking cessation as part of minor ailments
<b>Opioid harm reduction</b>	Provincially funded naloxone available through participating pharmacies	\$10 for dispensing injectable or intranasal provincially funded naloxone; \$25 for training for initial injectable naloxone (claims data n/a)	\$20.31 as of Apr 1, 2022, up from \$19.34 for training for provincially funded naloxone (11,769 claims)	
<b>Other services</b>		<ul style="list-style-type: none"> <li>COVID-19: \$42 for specimen collection for lab PCR test; \$15 for handling self-collected specimen for PCRT, increasing to \$35 when pharmacist orders and dispenses kit</li> <li>Authority to perform a procedure below the dermis for education and demonstration</li> <li>Authority to administer certain drugs by inhalation for education and demonstration</li> </ul>	As of Apr 1, 2022: \$9.96 up from \$9.62 per transmission of medication profile (221,208 claims); \$27.74 up from \$26.42 per hospital discharge support (62,158); \$44.63 up from \$42.50 per prescriber-requested consult (17,359); \$33.30 up from \$31.71 per palliative care support (8,847); \$19.65 per consult for medical abortion (450); \$31.98 per on-call service	

All content in RED indicates public funding is available only to eligible beneficiaries of the provincial drug plan. NOTES: Information current as of January 20, 2023. Claims data are for fiscal year ending March 31, 2022 unless other stated. In **New Brunswick and Nova Scotia**, claims data for COVID-19 vaccinations are estimates since data for fiscal year ending March 31, 2022 not available at time of compilation. In **Nova Scotia**, claims data for flu vaccinations not available at time of compilation. In **Manitoba**, claims for vaccinations may include non-publicly funded vaccines. In **Québec**, private insurance plans pay the same professional service fees as the public plan, for most but not all of the services listed here. In **all provinces**, pharmacists have authority to prescribe emergency refills.

SOURCES: Provincial pharmacy associations, provincial ministries of health, Neighbourhood Pharmacy Association of Canada (Pharmacy Services and Remuneration Summary, August 2022), Canadian Pharmacists Association (Injection Authority and Vaccine Administration chart, June 2022), Neighbourhood Pharmacies COVID-19 Vaccine Update (Apr 14-20, 2022).

## Professional services, fees and claims data for government-sponsored pharmacy programs, by province • As of January 20, 2023

	Nova Scotia	Prince Edward Island	Newfoundland and Labrador
<b>Care plans</b>			
<b>Medication reviews/ management</b>	\$52.50 per Basic Medication Review (6,876 claims); \$150 per Advanced Medication Review for seniors (2,460); \$20 per follow-up, max. 2 annually (558)	\$52.50 per Basic Medication Review (3,183 claims); \$65 per Diabetes Medication Review (1,473); \$20 per follow-up for Basic Medication Review, max. 4 annually (2,854); \$25 per follow-up for Diabetes Medication Review, max. 4 annually (1,220)	\$52.50 per Medication Review, max. 72/ pharmacy annually (2,486 claims)
<b>Pharmaceutical opinions</b>			
<b>Vaccination</b>	\$12.55 for flu (2021-22 claims n/a SEE NOTES); \$18 for COVID-19 (est. 1,350,000 claims SEE NOTES); authority for other vaccinations, inc. travel vaccines	\$13 for flu (33,607 claims); \$20 for COVID-19 as of Jan. 1, 2022 (up from \$15 since Jun. 1, 2021, up from \$13) (84,446 claims); \$20 for Shingrix as of Feb. 22, 2022 (5,494); authority for other vaccinations, inc. travel vaccines	\$13 for flu (76,415 claims); \$17 for COVID-19 as of Jan. 20, 2022 (up from \$13) (146,826); authority for other vaccinations, inc. travel vaccines
<b>Administration of drugs by injection</b>	Authority to administer drugs by injection	Authority to administer drugs by injection	Authority to administer drugs by injection
<b>Prescribing: renewals and adaptations</b>	\$20 per renewal for 4 or more prescriptions (12,998 claims) or \$12 for up to 3 (169,401); <b>\$14 per Prescription Adaptation (777)</b>	\$20 per renewal as of Oct. 18, 2022, max. 4 annually; <b>\$14.83 per adaptation (293 claims)</b>	\$11.96-\$12 per Medication Management adaptation (88,208 claims)
<b>Prescribing: common or minor ailments</b>	<ul style="list-style-type: none"> <li>\$20 per assessment with or without prescribing for herpes zoster (1,249 claims), Lyme disease (claims n/a) and UTIs (16,071), max. 2 annually/ condition; authority for 35 conditions in total</li> <li>\$20 per annual assessment with or without prescribing for Contraception Management (3,149); \$20 per follow-up with change in prescription, max. 1 annually; \$12 per follow-up with no change, max. 1 annually (1,686)</li> </ul>	\$25 per assessment with or without prescribing as of Oct. 18, 2022 (from \$20 for UTIs only); authority for 31 conditions in total (3,709 claims for UTIs)	Authority to assess and prescribe for 29 conditions
<b>Prescribing: initial access or to manage ongoing therapy</b>	Authority to assess and prescribe in emergencies; for preventable diseases (e.g., HPV, varicella); for diagnosis provided by primary care provider	Authority to assess and prescribe in emergencies	Authority to assess and prescribe for 19 preventable diseases (e.g., HPV, varicella)
<b>COVID-19 prevention and treatment</b>	<ul style="list-style-type: none"> <li>\$20 per assessment with or without prescribing for budesonide</li> <li>Selected pharmacies dispense Paxlovid; usual dispensing fee plus \$3.50</li> </ul>	<ul style="list-style-type: none"> <li>\$25 per assessment with or without prescribing as part of common ailments</li> <li>Usual dispensing fee plus \$5 for participating pharmacies to dispense Paxlovid</li> </ul>	\$20 to assess and prescribe Paxlovid (2,853 claims, May 16 to Sep. 25, 2022) plus \$11.96 to dispense (2,228) plus \$7.50 to provide rapid antigen test (1,093)
<b>Therapeutic substitution</b>	<b>\$26.25 (320 claims)</b>	<b>\$14.83 (25 claims)</b>	<b>\$11.96-\$12 (usual dispensing fee)</b>
<b>Trial prescriptions &amp; refusals to fill</b>	\$14 per refusal (29 claims)	<b>\$14.83 per refusal (40 claims)</b>	<b>\$23.92-\$24 per refusal (claims n/a)</b>
<b>Deprescribing</b>			<b>\$23 per assessment for SaferMedsNL (1,454 claims for PPIs, 1,085 for sedatives); \$10 per follow-up (348 for PPIs, 193 for sedatives)</b>
<b>Ordering laboratory tests</b>	Authority to order lab tests pending health system operationalization	Authority to order lab tests pending health system operationalization	
<b>Point of care testing (POCT)</b>	<ul style="list-style-type: none"> <li>Authority to perform any POCT for medication management</li> <li>\$50 per month for Community Pharmacist-led Anticoagulation Management Service inc. INR test</li> <li>Authority to administer rapid antigen test for COVID-19 and certify result for the purpose of travel</li> </ul>	Authority to perform glucose, HbA1C and INR tests pending regulations	
<b>Smoking cessation</b>	Authority to prescribe for smoking cessation as part of minor ailments	Authority to prescribe for smoking cessation as part of common ailments	Authority to prescribe for smoking cessation as part of minor ailments
<b>Opioid harm reduction</b>	\$25 for dispensing and education for provincially funded naloxone (claims n/a)		\$3 per carry for opioid agonist therapy (OAT, claims n/a); \$50 per delivery of OAT for those isolating due to COVID-19 (195 claims)
<b>Other services</b>			<ul style="list-style-type: none"> <li>\$50 per assessment and dispensing for medical abortion</li> <li>Authority to administer drugs by inhalation</li> </ul>

All content in **RED** indicates public funding is available only to eligible beneficiaries of the provincial drug plan.  
 NOTES: Information current as of January 20, 2023. Claims data are for fiscal year ending March 31, 2022 unless other stated. In **New Brunswick and Nova Scotia**, claims data for COVID-19 vaccinations are estimates since data for fiscal year ending March 31, 2022 not available at time of compilation. In **Nova Scotia**, claims data for flu vaccinations not available at time of compilation. In **Manitoba**, claims for vaccinations may include non-publicly funded vaccines. In **Québec**, private insurance plans pay the same professional service fees as the public plan, for most but not all of the services listed here. In **all provinces**, pharmacists have authority to prescribe emergency refills.

SOURCES: Provincial pharmacy associations, provincial ministries of health, Neighbourhood Pharmacy Association of Canada (Pharmacy Services and Remuneration Summary, August 2022), Canadian Pharmacists Association (Injection Authority and Vaccine Administration chart, June 2022), Neighbourhood Pharmacies COVID-19 Vaccine Update (Apr 14-20, 2022).